A Study to Learn About the Study Medicine Called PF-07976016 in Adults With Obesity
- Registration Number
- NCT06717425
- Lead Sponsor
- Pfizer
- Brief Summary
The purpose of this clinical trial is to learn about the safety and effects of the study medicine (called PF-07976016) for the potential treatment of obesity. The study will compare the experiences of participants taking the study medicine (PF-07976016) to those of participants who take placebo (a lookalike substance that contains no active study medicine). The aim is to measure the body's response to the study medicine, including any changes in participants' body weight and how well they tolerate the study medicine.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- All
- Target Recruitment
- 252
- Male or non-pregnant, non-breastfeeding female, 18 to 74 years of age at Visit 1
- Body Mass Index ≥30.0 kg/m2 at Visit 1, with stable body weight, defined as <5 kg change in the 12 weeks before Visit 1
- Eligible and willing to receive required background medicine
- Willing and able to comply with all study procedures
Key
- Any medical or psychiatric condition or laboratory abnormality, or recent serious illness or hospitalization, that may increase the risk of study participation or, in the investigator's judgment, make the participant inappropriate for the study including diagnosis of type 2 diabetes mellitus, type 1 or secondary forms of diabetes.
- Use of any prohibited prior or concomitant medication(s)
- Presence of specified abnormalities on diagnostic assessments including clinical laboratory tests at Visit 1.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description PF-07976016 Dose 1 PF-07976016 - PF-07976016 Dose 2 PF-07976016 - PF-07976016 Dose 3 PF-07976016 - Placebo Placebo -
- Primary Outcome Measures
Name Time Method Percent change from baseline in body weight Baseline to Week 16
- Secondary Outcome Measures
Name Time Method Number of participants with treatment emergent adverse events From first dose (Day 1) up to 28-35 days after final dose, a total of approximately 21 weeks
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
Trial Locations
- Locations (20)
Artemis Institute for Clinical Research
🇺🇸San Diego, California, United States
Westside Center for Clinical Research
🇺🇸Jacksonville, Florida, United States
New Horizon Research Center
🇺🇸Miami, Florida, United States
St Johns Center for Clinical Research
🇺🇸Saint Augustine, Florida, United States
Rophe Adult and Pediatric Medicine/SKYCRNG
🇺🇸Union City, Georgia, United States
East-West Medical Research Institute
🇺🇸Honolulu, Hawaii, United States
L-MARC Research Center
🇺🇸Louisville, Kentucky, United States
Rochester Clinical Research, LLC
🇺🇸Rochester, New York, United States
Alliance for Multispecialty Research, LLC
🇺🇸Norman, Oklahoma, United States
Cornerstone Nutrition and Diabetes
🇺🇸Norman, Oklahoma, United States
Capital Area Research, LLC
🇺🇸Camp Hill, Pennsylvania, United States
Elligo Clinical Research Center
🇺🇸Austin, Texas, United States
Texas Diabetes & Endocrinology, P.A.
🇺🇸Austin, Texas, United States
Velocity Clinical Research, Dallas
🇺🇸Dallas, Texas, United States
UT Southwestern Medical Center
🇺🇸Dallas, Texas, United States
Consano Clinical Research, LLC
🇺🇸Shavano Park, Texas, United States
Chrysalis Clinical Research
🇺🇸Saint George, Utah, United States
Southwest Internal Medicine, PC
🇺🇸Saint George, Utah, United States
Milestone Research Inc.
🇨🇦London, Ontario, Canada
Canadian Phase Onward
🇨🇦Toronto, Ontario, Canada